Could 68Ga-somatostatin analogues be an important alternative to 18F-DOPA PET/CT in pediatrics?
暂无分享,去创建一个
[1] C. Hovendal,et al. 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[2] M. Severino,et al. Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F–DOPA PET , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[3] A. Piccardo,et al. Neuroblastoma: MIBG Imaging and New Tracers. , 2017, Seminars in nuclear medicine.
[4] K. Langen,et al. (18)F-DOPA Positron Emission Tomography in Medulloblastoma: 2 Case Reports. , 2016, World neurosurgery.
[5] Ian Law,et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.
[6] A. Hogg,et al. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma , 2016, Journal of pediatric hematology/oncology.
[7] M. Severino,et al. Ability of 18F-DOPA PET/CT and fused 18F-DOPA PET/MRI to assess striatal involvement in paediatric glioma , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[8] A. Luxen,et al. Automated production at the curie level of no-carrier-added 6-[(18)F]fluoro-L-dopa and 2-[(18)F]fluoro-L-tyrosine on a FASTlab synthesizer. , 2015, Journal of labelled compounds & radiopharmaceuticals.
[9] S. Vajapeyam,et al. 18F-FDG PET and MR Imaging Associations Across a Spectrum of Pediatric Brain Tumors: A Report from the Pediatric Brain Tumor Consortium , 2014, The Journal of Nuclear Medicine.
[10] T. Luo,et al. Characterization of Neuroblastic Tumors Using 18F-FDOPA PET , 2013, The Journal of Nuclear Medicine.
[11] G. Treglia,et al. Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis , 2012, Pediatric Radiology.
[12] Dinesh Kumar Yadav,et al. Persistent hyperinsulinemic hypoglycemia of infancy , 2012, Journal of pediatric endocrinology & metabolism : JPEM.
[13] F. Brunelle,et al. Congenital hyperinsulinism: current trends in diagnosis and therapy , 2011, Orphanet journal of rare diseases.
[14] M. Gaze,et al. 177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma , 2011, The Journal of Nuclear Medicine.
[15] A. Pierro,et al. Surgical management of congenital hyperinsulinism of infancy. , 2011, Seminars in pediatric surgery.
[16] C. Decristoforo,et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[17] C. Nanni,et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[18] S. Keir,et al. [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma. , 2010, Current radiopharmaceuticals.
[19] C. Decristoforo,et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[20] A. Bhattacharya,et al. Novel Use of Somatostatin Receptor Scintigraphy in Localization of Focal Congenital Hyperinsulinism: Promising but Fallible , 2009, Journal of pediatric endocrinology & metabolism : JPEM.
[21] R. Packer,et al. Management of and prognosis with medulloblastoma: therapy at a crossroads. , 2008, Archives of neurology.
[22] R. Chirakal,et al. Trifluoromethanesulfonic acid, an alternative solvent medium for the direct electrophilic fluorination of DOPA: new syntheses of 6-[18F]fluoro-L-DOPA and 6-[18F]fluoro-D-DOPA , 2007 .
[23] N. Boddaert,et al. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[24] U. Bode,et al. 111In-Pentetreotide scintigraphy in medulloblastoma: A comparison with magnetic resonance imaging , 2007, Acta oncologica.
[25] R. Coleman,et al. [18F]Fluorodeoxyglucose-Positron Emission Tomography in Patients with Medulloblastoma , 2004, Neurosurgery.
[26] M. Frühwald,et al. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma , 1998, Journal of Neuro-Oncology.
[27] C. Daumas-Duport,et al. Comparison of Somatostatin Receptor Expression in Human Gliomas and Medulloblastomas , 2002, Journal of neuroendocrinology.
[28] J. Rivier,et al. Somatostatin receptor gene expression in neuroblastoma , 2000, Regulatory Peptides.
[29] M. Thangaraju,et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. , 1999, Diabetes.
[30] M. O'dorisio,et al. Characterization of somatostatin receptors on human neuroblastoma tumors. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.